CIR

EQS-News: Strong earnings power allows for active risk management in 2023 – consolidated operating profit expected to rise to between €300 million and €350 million in 2024

Retrieved on: 
Wednesday, March 13, 2024

Consolidated operating profit is projected to rise to between €300 million and €350 million in 2024, even though the Bank anticipates continued above-average risk provisions.

Key Points: 
  • Consolidated operating profit is projected to rise to between €300 million and €350 million in 2024, even though the Bank anticipates continued above-average risk provisions.
  • Aareal Bank Group closed the 2023 financial year with consolidated operating profit of €149 million (2022: €239 million).
  • Thanks to its strong earnings power, the Group nonetheless anticipates consolidated operating profit between €300 million and €350 million.
  • The Bank is expected to achieve operating profit of €250 million to €300 million, despite risk provisions projected to remain at above-average levels.

EQS-News: Allianz SE: Allianz achieves record operating profit and shareholders’ core net income

Retrieved on: 
Wednesday, March 13, 2024

“Allianz extended our track record of delivering a record operating profit and core net income, consolidating our leading position as one of the world’s most resilient global insurers and active asset managers.

Key Points: 
  • “Allianz extended our track record of delivering a record operating profit and core net income, consolidating our leading position as one of the world’s most resilient global insurers and active asset managers.
  • Shareholders’ core net income increased to 2.4 (1.6) billion euros due to a higher operating profit and non-operating result.
  • 3 Core EPS and core RoE calculation based on shareholders‘ core net income.
  • “We’ve achieved another year of record results and all operating segments finished the year above or close to their operating profit target mid-points.

EQS-News: GRENKE ACHIEVES UPPER HALF OF 2023 PROFIT FORECAST – NEW LEASING BUSINESS OF OVER EUR 3 BILLION TARGETED FOR 2024

Retrieved on: 
Wednesday, March 13, 2024

Consolidated Group net profit reaches EUR 86.7 million (2022: EUR 84.2 million)

Key Points: 
  • Consolidated Group net profit reaches EUR 86.7 million (2022: EUR 84.2 million)
    Proposed dividend of EUR 0.47 per share (2022: EUR 0.45)
    Baden-Baden, March 7, 2024: GRENKE AG, a global financing partner for small and medium-sized enterprises, achieved Consolidated Group net profit of EUR 86.7 million in the 2023 financial year (2022: EUR 84.2 million), reaching the upper half of its forecast range of EUR 80 to 90 million.
  • New leasing business in 2023 came to a total of EUR 2.6 billion (2022: EUR 2.3 billion).
  • As of the December 31, 2023 reporting date, non-current lease receivables of EUR 3.6 billion (2022: EUR 3.3 billion) compared to non-current financial liabilities of EUR 3.6 billion (2022: EUR 2.5 billion).
  • Current lease receivables of EUR 2.1 billion (2022: EUR 2.0 billion) were at a similar level to current financial liabilities of EUR 1.8 billion (2022: EUR 2.2 billion).

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

Retrieved on: 
Monday, February 26, 2024

Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.

Key Points: 
  • Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.
  • The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the original submission.
  • AB Science provided a methodologically justified new claim “patients with ALS prior to any loss of function”, where CAFS and Overall Survival (OS) are significantly improved.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.

Kyriba’s Quarterly Currency Impact Report: Currency Impact Reported by North American and European Companies Totaled $30 Billion

Retrieved on: 
Thursday, February 15, 2024

Kyriba’s latest Currency Impact Report (CIR) found that the currency impact on earnings reported by both North American and European companies totaled $30 billion in Q3 2023 ($16.01 billion headwinds and $13.92 billion tailwinds).

Key Points: 
  • Kyriba’s latest Currency Impact Report (CIR) found that the currency impact on earnings reported by both North American and European companies totaled $30 billion in Q3 2023 ($16.01 billion headwinds and $13.92 billion tailwinds).
  • Highlights from the Q3 2023 Kyriba Currency Impact Report include:
    Publicly traded North American companies reported $16.01 billion in headwinds.
  • Publicly traded North American companies reported $13.92 billion in tailwinds.
  • The average earnings per share (EPS) impact reported by North American companies in Q3 2023 was $0.05, five times greater than the industry standard MBO of less than $0.01 EPS impact.

Sixteen Firms to Pay More Than $81 Million Combined to Settle Charges for Widespread Recordkeeping Failures

Retrieved on: 
Friday, February 9, 2024

The Huntington Investment Company self-reported and was ordered to pay lower civil penalty than other firms

Key Points: 
  • The firms did not maintain or preserve the substantial majority of these off-channel communications, in violation of the federal securities laws.
  • By failing to maintain and preserve required records, some of the firms likely deprived the SEC of these off-channel communications in various SEC investigations.
  • The failures involved employees at multiple levels of authority, including supervisors and senior managers.
  • In addition to the significant financial penalties, each of the firms was ordered to cease and desist from future violations of the relevant recordkeeping provisions and was censured.

EQS-News: DWS Returned to Net Inflows in 2023 Supported by all Three Pillars – Passive including Xtrackers, Active and Alternatives

Retrieved on: 
Monday, February 5, 2024

Net flows ex Cash of EUR 1.8bn in Q4 resulting in EUR 22.6bn in FY 2023 (including Cash EUR 11.0bn in Q4 2023, EUR 28.3bn in FY 2023), supported by all three pillars – Passive including Xtrackers, Active and Alternatives.

Key Points: 
  • Net flows ex Cash of EUR 1.8bn in Q4 resulting in EUR 22.6bn in FY 2023 (including Cash EUR 11.0bn in Q4 2023, EUR 28.3bn in FY 2023), supported by all three pillars – Passive including Xtrackers, Active and Alternatives.
  • Supported by all three pillars – Passive including Xtrackers, Active and Alternatives – DWS recorded net inflows (ex cash) of EUR 22.6 billion.
  • The adjusted Cost-Income Ratio at 64.0 percent in 2023 comfortably meets DWS’ outlook of below 65 percent for 2023.
  • Total net inflows in 2023 were mainly driven by Passive including Xtrackers and supported by Cash, Active (ex Cash) and Alternatives.

BRI's 2023 Stellar Performance: Earning Rp.60.4T Profits

Retrieved on: 
Thursday, February 1, 2024

JAKARTA, Indonesia, Jan. 31, 2024 /PRNewswire/ -- PT Bank Rakyat Indonesia (Persero) Tbk (IDX: BBRI) concluded 2023 with an exceptional financial performance, showcasing resilience and growth despite external challenges. The company's consolidated assets rose by 5.3% to IDR 1.965T, accompanied by a remarkable 17.5% year-on-year profit increase, reaching IDR 60.4T.

Key Points: 
  • The company's consolidated assets rose by 5.3% to IDR 1.965T, accompanied by a remarkable 17.5% year-on-year profit increase, reaching IDR 60.4T.
  • Effective risk management was another cornerstone of BRI's success, with Non-Performing Loans (NPL) controlled at 2.95% and NPL Coverage of 229.09%.
  • Despite high-interest rates, BRI achieved a 3.9% YoY deposit growth to IDR 1,358.3T by December 2023.
  • With over 740,000 agents, transactions reached IDR 1,427T in 2023, generating fee-based income of IDR 1.5T.

CENTOGENE Receives French Research Tax Credit Accreditation

Retrieved on: 
Wednesday, January 24, 2024

and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France.

Key Points: 
  • and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France.
  • Accordingly, it has received accreditation under the French R&D tax credit initiative ('Crédit d'Impôt Recherche', CIR) for a three-year period.
  • The CIR initiative enables eligible research-based companies, who are subject to corporate tax in France, to claim tax relief on 30% of all costs (up to €100 million) incurred in R&D activities outsourced to CENTOGENE.
  • Prof. Peter Bauer, Chief Medical & Genomic Officer at CENTOGENE, stated, “'We are excited to receive this accreditation as it recognizes our advanced research capabilities that we support our customers with.

Immuron Clinical Trials Update

Retrieved on: 
Friday, December 22, 2023

MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio.

Key Points: 
  • The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
  • Headline results from the clinical trial are anticipated to be reported in H2 2024.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM).
  • The inpatient challenge phase of the Travelan clinical study led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed.